Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe

Leukemia

Volumn 11, Issue 7, 1997, Pages 1147-1155

  Kuhnel J M ^a,d   Perrot, J Y ^b   Faussat, A M ^c   Marie, J P ^b,c   Schwaller, M A ^a  

^a UNIVERSITÉ PARIS SUD   (France)

^b Hop d'Enfants Armand Trousseau   (France)

^c HÔTEL DIEU   (France)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

JC 1 and rhodamine 123 accumulation; K562; Modulators; MRK 16; Multidrug resistance; UIC2

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; ANTIBODY; CARBOCYANINE; CYCLOSPORIN A; DOXORUBICIN; FLUORESCENT DYE; GLYCOPROTEIN P; VERAPAMIL;

ARTICLE; ASSAY; CELL STRAIN K 562; CONTROLLED STUDY; CYTOPLASM; DRUG ACCUMULATION; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; MITOCHONDRION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0030874190     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400698     Document Type: Article

References (14)

1. Acerci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993; 81: 2215-2222.
2. Zhou DC, Zittoun R, Marie JP. Homoharringtonine - an effective new natural product in cancer chemotherapy (review). Bull Cancer 1995; 82: 987-995.
3. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993; 62: 85-427.
4. Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994; 91: 497-504.
5. Dhainaut A, Réginier G, Atassi G, Pierré A, Léonce S, Kraus-Berthier L, Prost JF. New triazine derivatives as potent modulators of multidrug resistance. J Med Chem 1992; 35: 2481-2496.
6. Ford MJ, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-199.
7. Ford JM. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers (review). Eur J Cancer 1996; 32A: 991-1001.
8. Patel HL, Rothenber ML. Multidrug resistance in cancer chemotherapy. Invest New Drugs 1994; 12: 1-13.
9. Nooter K, Van Den Engh G, Sonneveld P. Quantitative flow cytometric determination of anthracyclin content of rat bone marrow cells. Cancer Res 1983; 43: 5126-5130.
10. Friedlander ML, Bell DR, Leary J, Davey RA. Comparison of Western blot analysis and immunocytochemical detection of P-glycoprotein in multidrug resistance cells. J Clin Pathol 1989; 42: 719-722.
11. Grogan TM, Dalton WS, Rybski JA, Spier C, Metzer PS, Richter L, Gleason MC, Pindur J, Cline A, Scheper R. Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest 1990; 63: 815-824.
12. Kioka N, Yamano Y, Komamano T, Ueda K. Heat-shock responsive elements in the induction of the multidrug resistance gene (MDR1). FEBS Lett 1992; 301: 37-40.
13. Marie JP, Zittoun R, Sikik BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlation with treatment outcome and in vitro sensitivity. Blood 1991; 78: 586-592.
14. Ueda K, Yamano Y, Kioka N, Kakehi Y, Yoshida O, Gottesman MM, Pastan IA, Komano T. Detection of multidrug resistance (MDR1) gene RNA expression in human tumors by a sensitive ribonuclease protection assay. Jpn J Cancer Res 1989; 80: 1127-1132.